Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01357668 · ClinicalTrials.gov registry record
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
A clinical trial of Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 800
- Enrollment target
- 20
- Study locations
NCT01357668: Active study of Juvenile Idiopathic Arthritis, sponsored by Bristol-Myers Squibb.
NCT01357668 is a study of Juvenile Idiopathic Arthritis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 800 participants, above the 203-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (294% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01357668, a study of Juvenile Idiopathic Arthritis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
Conditions Studied
Study Locations (20)
Other
- Local Institution - 0025 - Bregenz
- Local Institution - 0002 - Innsbruck
- Local Institution - 0032 - Vienna
- Local Institution - 0027 - Rio de Janeiro
- Local Institution - 0012 - Copenhagen
- Local Institution - 0005 - Paris
- Local Institution - 0041 - Toulouse
- Local Institution - 0003 - Bad Bramstedt
- Local Institution - 0030 - Berlin
- Local Institution - 0034 - Freiburg im Breisgau
São Paulo
- Local Institution - 0010 - Botucatu
- Local Institution - 0026 - Campinas
- Local Institution - 0028 - São Paulo
Arkansas
- Local Institution - 0060 - Little Rock
New Jersey
- Local Institution - 0001 - Princeton
Ohio
- Local Institution - 0059 - Cincinnati
Alberta
- Local Institution - 0029 - Calgary
Quebec
- Local Institution - 0011 - Montreal
Central Jutland
- Local Institution - 0035 - Aarhus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2013-01-30 |
| Est. Completion | 2029-01-02 |
What the registry record for NCT01357668 still lists
NCT01357668 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 203-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (294% higher).
The record links to 1 condition, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT01357668 names 20 study sites across 9 states, led by Other, São Paulo, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01357668 about?
NCT01357668 is a clinical study titled "An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis". The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
What is the current status of trial NCT01357668?
This trial is currently active not recruiting. The enrollment target is 800 participants. The study started on 2013-01-30. Estimated completion is 2029-01-02.
What conditions does trial NCT01357668 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis.
Who is sponsoring clinical trial NCT01357668?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01357668 being conducted?
This trial has 20 study locations across Arkansas, New Jersey, Ohio, São Paulo, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01357668's enrollment target sits among peer trials
800 2nd of 8 the highest of 8 other Juvenile Idiopathic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Juvenile Idiopathic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
RECRUITING · Phase 3
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
Juvenile Idiopathic Arthritis (JIA) Registry
COMPLETED
-
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
COMPLETED · Phase 2
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI